INFI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the historical short interest of Infinity Pharmaceuticals Inc, as measured by the Short Percentage Of Float.
This the Institutional Ownership History of Infinity Pharmaceuticals IncPeter Lynch prefers to buy companies with low institutional ownership.
This is the historical insider ownership of Infinity Pharmaceuticals Inc. It is usually better to buy companies with large insider ownership. The company insiders' interest are more aligned with external shareholders in this case.
|Holder||Position||Shares||% of Shares |
|Ms. Adelene Q. Perkins||Pres & CEO||447,535||0.92%||2013-09-12|
|Dr. Anthony B. Evnin,PhD||Director||91,900||0.19%||2014-10-03|
|Dr. Michael C. Venuti,PhD||N/A||56,250||0.12%||2013-03-06|
|Dr. Franklin H. Moss,PhD||N/A||33,154||less than 0.1%||2006-09-12|
|Dr. David Schnell,M.D.||N/A||26,938||less than 0.1%||2006-09-12|
|Dr. Alexander E. Barkas,PhD||N/A||26,938||less than 0.1%||2006-09-12|
|Tong Jeffrey K||N/A||17,246||less than 0.1%||2010-01-01|
|Dr. Arnold J. Levine,PhD||N/A||15,287||less than 0.1%||2007-03-01|
|D. Ronald Daniel||N/A||13,261||less than 0.1%||2006-09-12|
|Holder||Shares||Report Date||% of Shares |
|% of Total |
|Orbimed Advisors, LLC||4,736,900||2014-09-30||9.72||0.66||63,569,000|
|BlackRock Advisors LLC||4,684,696||2014-12-31||9.61||0.00||79,124,515|
|Deerfield Management Co||3,882,805||2014-09-30||7.97||1.90||52,107,000|
|Point72 Capital Advisors, Inc.||3,411,659||2014-04-07||7.03||0.00||40,564,626|
|Fidelity Management and Research Company||3,373,942||2014-09-30||6.92||0.01||45,278,000|
|Goldman Sachs Asset Management, L.P.||2,878,826||2014-09-30||5.91||0.04||38,634,000|
|Vanguard Group, Inc.||2,723,533||2014-09-30||5.59||0.00||36,550,000|
|BB Biotech AG||2,520,737||2015-01-08||5.17||0.00||42,575,248|
|Bb Biotech AG||2,320,737||2014-09-30||4.75||1.03||31,083,203|
|Bellevue Asset Management AG||2,320,737||2014-09-30||4.75||1.03||31,083,203|